This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Cramer's 'Mad Money' Recap: Living Large

Basically the entire planet is the company's bright spot. Pinchuk said sales remain strong in Asia and yes, even in Europe. He was especially enthusiastic about China since, unlike America where there are 300 million cars on average 11 year old, China has 60 million cars, most of which are brand new. That means the coming boom in auto repair has yet to begin and Snap-on is positioning itself to become a dominant player.

Cramer once again praised Snap-on for proving that quality products can indeed be made in America. He continued his recommendation of the stock.

Know Your IPO

In the "Know Your IPO" segment, Cramer followed up on a few recent initial public offerings to separate the good from the bad and the ugly. He said Thursday's IPO of dollar store chain Five Below (FIVE) rallied as expected, giving investors a 53% gain. But they must now keep their discipline and take profits.

So what of other recent IPOs? Cramer said Synacor (SYNC) and Supernus Pharmaceuticals (SUPN) have both been winners and investors need to take a victory lap and take profits. Synacor is up 160% since its IPO, while Supernus has delivered a 197% gain.

In the loser's corner, Cramer singled out Ignite Restaurant Group (IRG), which announced "accounting irregularities," and WageWorks (WAGE), a stock that's now "priced for perfection." Cramer said both of these stocks need to be sold with prejudice.

Finally, Cramer noted Merrimack Pharmaceuticals (MACK), a recent IPO that's still worth buying. He said that while speculative, Merrimack concentrates on orphan drugs that often receive special treatment at the Food and Drug Administration. The company is also partnering with Sanofi-Aventis (SNY) on a breast cancer treatment that could be a $1.3 billion opportunity.

Investing in Merrimack is playing FDA approval roulette, noted Cramer, but the stock is cheap enough that the company only needs one of its drugs to win in order to rewards shareholders. He said there's no catalyst for the stock, so there's no hurry to get in now.

Lightning Round

Here's what Cramer had to say about callers' stocks during the "Lightning Round":

American Capital Agency (AGNC): "They keep doing equity offerings, but they're working so I'll stick with it."

2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,581.83 -32.98 -0.20%
S&P 500 1,944.31 +3.03 0.16%
NASDAQ 4,419.2220 -0.2560 -0.01%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs